CN1771037A - 包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途 - Google Patents

包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途 Download PDF

Info

Publication number
CN1771037A
CN1771037A CNA2004800093693A CN200480009369A CN1771037A CN 1771037 A CN1771037 A CN 1771037A CN A2004800093693 A CNA2004800093693 A CN A2004800093693A CN 200480009369 A CN200480009369 A CN 200480009369A CN 1771037 A CN1771037 A CN 1771037A
Authority
CN
China
Prior art keywords
pyridine
amino
benzoyl
sulfonyl
tetrahydrothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800093693A
Other languages
English (en)
Chinese (zh)
Inventor
P·格雷戈尔
N·哈里斯
J·科佩
R·朱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rimonyx Pharmaceuticals Ltd
Original Assignee
Rimonyx Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rimonyx Pharmaceuticals Ltd filed Critical Rimonyx Pharmaceuticals Ltd
Publication of CN1771037A publication Critical patent/CN1771037A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
CNA2004800093693A 2003-02-05 2004-02-05 包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途 Pending CN1771037A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL154306 2003-02-05
IL15430603A IL154306A0 (en) 2003-02-05 2003-02-05 Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof

Publications (1)

Publication Number Publication Date
CN1771037A true CN1771037A (zh) 2006-05-10

Family

ID=30011984

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800093693A Pending CN1771037A (zh) 2003-02-05 2004-02-05 包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途

Country Status (10)

Country Link
US (1) US7365080B2 (enExample)
EP (1) EP1589970A4 (enExample)
JP (1) JP2006516610A (enExample)
KR (1) KR20050100655A (enExample)
CN (1) CN1771037A (enExample)
AU (1) AU2004210241A1 (enExample)
CA (1) CA2515102A1 (enExample)
IL (1) IL154306A0 (enExample)
MX (1) MXPA05008397A (enExample)
WO (1) WO2004069149A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829629A (zh) * 2015-03-26 2015-08-12 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3-c]吡啶衍生物、其制备方法和用途
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
CN110300596A (zh) * 2017-01-13 2019-10-01 东菱药品工业株式会社 嗜中性粒细胞活化调节剂

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275214A1 (en) * 2003-12-30 2006-12-07 Rimonyx Pharmaceuticals Ltd. Methods of screening for anti-inflammatory drugs and use thereof
WO2005089068A2 (en) * 2004-03-24 2005-09-29 Rimonyx Pharmaceuticals Ltd. Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
DK1753512T3 (da) 2004-05-28 2008-11-17 4Sc Ag Tetrahydropyridothiophener
ATE397000T1 (de) 2004-06-04 2008-06-15 Nycomed Gmbh Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
WO2005120642A2 (en) 2004-06-11 2005-12-22 Altana Pharma Ag Tetrahydropyridothiophenes for treating hyperproliferative disorders
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
AU2006212224A1 (en) 2005-02-09 2006-08-17 4Sc Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
CA2596501A1 (en) 2005-02-11 2006-08-17 Altana Pharma Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
WO2006125815A2 (en) * 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
CA2609003A1 (en) 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
US20100298370A1 (en) * 2006-03-20 2010-11-25 Paul Gregor Benzothiazolyl thienopyridine derivatives and uses thereof
CN101821271A (zh) * 2007-08-15 2010-09-01 先灵公司 可用于抑制1型11β-羟基类固醇脱氢酶的6-取代的磺酰基氮杂双环[3.2.1]辛烷类
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
WO2010003023A2 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
DK2403499T3 (da) * 2009-03-02 2019-12-09 Stemsynergy Therapeutics Inc Fremgangsmåder og sammensætninger til anvendelse i behandling af cancer og reduktion af wnt-medierede virkninger i en celle
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
WO2012148889A1 (en) * 2011-04-28 2012-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human apurinic/apyrimidinic endonuclease 1
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX2014006373A (es) * 2011-11-29 2014-07-22 Gilead Pharmasset Llc Composiciones y metodos para tratar el virus de la hepatitis c.
WO2016197078A1 (en) * 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
US10106290B2 (en) 2015-12-14 2018-10-23 Westrock Shared Services, Llc Carton, blank, and method of folding
US10647725B2 (en) * 2016-04-21 2020-05-12 The University Of Toledo Anti-infective 2-aminothiophenes
EP3562818B1 (en) 2016-12-29 2022-05-18 ENYO Pharma Thiophene derivatives as antiviral agents
WO2021050994A1 (en) * 2019-09-13 2021-03-18 Aerie Pharmaceuticals, Inc. Heterobicyclic carboxamides and uses thereof
EP4398902A4 (en) * 2021-09-07 2025-10-01 Gismo Therapeutics Inc PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT AND USE THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517396A (ja) * 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) * 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP4548882B2 (ja) * 1999-11-30 2010-09-22 興和創薬株式会社 ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829629A (zh) * 2015-03-26 2015-08-12 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3-c]吡啶衍生物、其制备方法和用途
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
CN110300596A (zh) * 2017-01-13 2019-10-01 东菱药品工业株式会社 嗜中性粒细胞活化调节剂

Also Published As

Publication number Publication date
WO2004069149A2 (en) 2004-08-19
US20060135529A1 (en) 2006-06-22
EP1589970A2 (en) 2005-11-02
EP1589970A4 (en) 2008-05-21
JP2006516610A (ja) 2006-07-06
WO2004069149A3 (en) 2004-11-25
KR20050100655A (ko) 2005-10-19
CA2515102A1 (en) 2004-08-19
AU2004210241A1 (en) 2004-08-19
US7365080B2 (en) 2008-04-29
IL154306A0 (en) 2003-09-17
MXPA05008397A (es) 2006-02-17

Similar Documents

Publication Publication Date Title
CN1771037A (zh) 包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途
CN1253150C (zh) 单独的或与抗血小板聚集药物联合的Xa因子抑制剂
CN100335479C (zh) 糖元合成酶激酶3的双环抑制剂
CN100345830C (zh) 稠合杂芳基衍生物
CN1233188A (zh) 含Rho激酶抑制剂的药物制剂
CN1198804C (zh) 酰胺化合物及其用途
CN1798749A (zh) 作为抗癌剂的杂芳基－稠合的嘧啶基化合物
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1649581A (zh) 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
CN1835948A (zh) 2－酰基氨基噻唑衍生物或其盐
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1478085A (zh) 用于治疗冠状动脉疾病或动脉粥样硬化的abca-1提高化合物
CN1694879A (zh) 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
CN101048399A (zh) 4－杂芳基甲基取代的酞嗪酮衍生物
CN1433312A (zh) 作为治疗剂的巴比妥酸类似物
CN1688577A (zh) 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
CN1774433A (zh) 作为胰高血糖素受体拮抗剂的取代的3－氰基噻吩乙酰胺
CN1291978A (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1394203A (zh) 用作5－ht2a受体拮抗剂的哌啶和哌嗪衍生物
CN1244798A (zh) 磺酸或磺酰氨基n－(杂芳烷基)－氮杂环酰胺化合物
CN1198649C (zh) 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
CN1805749A (zh) 星孢素衍生物的新药物用途
CN1333766A (zh) 取代的(氨基亚氨基甲基或氨基甲基)苯并杂芳基化合物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1353705A (zh) 吡嗪酮凝血酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication